GlaxoSmithKline PLC

13 يناير 2025، 07:14 ص UTC

GSK to Buy U.S. Rare Tumor Specialist IDRx for Up to $1.15 Billion

9 يناير 2025، 06:50 ص UTC

GSK in Talks to Buy U.S. Rare Tumor Specialist IDRx for up to $1 Billion, FT Says, Citing Sources

15 نوفمبر 2024، 10:28 ص UTC

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

30 أكتوبر 2024، 11:44 ص UTC

GSK Cuts Vaccine Sales Outlook Amid U.S. Weakness -- Update

30 أكتوبر 2024، 07:50 ص UTC

GSK Profit Rises on HIV, Cancer Treatments But Sales Slip on Weak U.S. Vaccine Demand

13 يناير 2025، 07:05 ص UTC

GSK Enters Agreement To Acquire IDRx, Inc. >GSK.LN

13 يناير 2025، 07:00 ص UTC

GSK to Buy U.S. Rare Tumor Specialist IDRx for Up to $1.15 Bln

13 يناير 2025، 07:00 ص UTC

GSK to Make $1B Upfront Payment

13 يناير 2025، 07:00 ص UTC

GSK to Buy IDRx for up to $1.15B

13 يناير 2025، 07:00 ص UTC

GSK: Acquisition Adds to Portfolio in Gastrointestinal Cancers

9 يناير 2025، 11:24 ص UTC

FDA Label Warning Threatens GSK's RSV Vaccine Sales -- Market Talk

9 يناير 2025، 06:35 ص UTC

GSK in Talks to Buy U.S. Rare Tumor Specialist IDRx for up to $1 Bln, FT Says, Citing Sources

15 نوفمبر 2024، 01:08 م UTC

Trump's RFK Pick Weighs on Vaccine Makers -- WSJ

15 نوفمبر 2024، 10:34 ص UTC

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

15 نوفمبر 2024، 10:29 ص UTC

Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ

7 نوفمبر 2024، 11:53 ص UTC

Moderna Earnings Beat Estimates. But Its Future Still Looks Uncertain. -- Barrons.com

7 نوفمبر 2024، 11:31 ص UTC

Moderna Earnings Beat Estimates. But Its Future Still Looks Uncertain. -- Barrons.com

31 أكتوبر 2024، 07:48 م UTC

AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- Update

30 أكتوبر 2024، 03:04 م UTC

GSK's 3Q Results Are a Mixed Bag -- Market Talk

30 أكتوبر 2024، 08:22 ص UTC

GSK's Vaccine Weakness Is a Major Concern -- Market Talk

30 أكتوبر 2024، 07:18 ص UTC

GSK Reiterates Guidance As HIV And Cancer Drug Demand Offset Vaccine Weakness -- MarketWatch

30 أكتوبر 2024، 07:04 ص UTC

GSK PLC Expects to deliver Around Middle of Existing Annual Guidance Ranges

30 أكتوبر 2024، 07:03 ص UTC

GSK PLC 3Q EPS 1.4p

30 أكتوبر 2024، 07:02 ص UTC

GSK PLC Had Seen 2024 Sales Growth of 7% to 9%

30 أكتوبر 2024، 07:02 ص UTC

GSK PLC Issues Dividend of 15p

30 أكتوبر 2024، 07:01 ص UTC

GSK PLC Had Seen 2024 Core Earnings Per Share Growth of 10% to 12%

30 أكتوبر 2024، 07:01 ص UTC

GSK PLC Had Seen 2024 Core Operating Pft Growth Between 11% and 13%

30 أكتوبر 2024، 07:01 ص UTC

GSK PLC Backs 2024 View

30 أكتوبر 2024، 07:00 ص UTC

Analysts Saw GSK PLC 3Q Net Pft GBP1.78B

30 أكتوبر 2024، 07:00 ص UTC

Analysts Saw GSK PLC 3Q Turnover GBP8.00B